NPM1
Early data for ziftomenib showed high rates of response with no signs of differentiation syndrome in patients with NPM1-mutated and KMT2A-rearranged AML.
Kura Oncology Prices $100M Public Offering
The firm will use the funds to advance its lead product candidate ziftomenib as a treatment for patients with NPM1-mutated acute myeloid leukemia.
The company will file an NDA by year-end after a third of refractory acute leukemia patients with KMT2A rearrangements or NPM1 mutations had a complete response in a trial.
Invivoscribe, Kronos Bio Partner on Companion Diagnostic Test for Leukemia Drug
The companion diagnostic assay would identify mutations in the NPM1 gene, which Kronos Bio is targeting with its investigational drug entospletinib.
FDA Lifts Partial Clinical Hold on Kura Oncology's AML Trial
The agency and company have agreed on a strategy to mitigate the differentiation syndrome that previously caused one patient's death in the study.